Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Socinski MA, et al. Among authors: rosenman jg. J Clin Oncol. 2004 Nov 1;22(21):4341-50. doi: 10.1200/JCO.2004.03.022. J Clin Oncol. 2004. PMID: 15514375 Clinical Trial.
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J; Carolina Conformal Therapy Consortium. Marks LB, et al. J Clin Oncol. 2004 Nov 1;22(21):4329-40. doi: 10.1200/JCO.2004.02.165. J Clin Oncol. 2004. PMID: 15514374 Clinical Trial.
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE. Socinski MA, et al. J Clin Oncol. 2008 May 20;26(15):2457-63. doi: 10.1200/JCO.2007.14.7371. J Clin Oncol. 2008. PMID: 18487565 Clinical Trial.
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
Higginson DS, Chen RC, Tracton G, Morris DE, Halle J, Rosenman JG, Stefanescu M, Pham E, Socinski MA, Marks LB. Higginson DS, et al. Among authors: rosenman jg. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e385-92. doi: 10.1016/j.ijrobp.2012.04.045. Epub 2012 Aug 1. Int J Radiat Oncol Biol Phys. 2012. PMID: 22857887
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, Mavroidis P, Lee CB, Jensen BC, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB. Wang K, et al. Among authors: rosenman jg. J Clin Oncol. 2017 May 1;35(13):1387-1394. doi: 10.1200/JCO.2016.70.0229. Epub 2017 Jan 23. J Clin Oncol. 2017. PMID: 28113017 Free PMC article. Clinical Trial.
114 results